Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | BHMT | Q93088 | 4/20 | 0.33 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13294502 | 0.79 | RNPEP (0.41) | RNPEPANPEPENPEPMETAP2METAP1 | |
| Methionine SCHEMBL8402808 | 0.75 | BHMT (0.52) | RNPEPNOS2NOS3NOS1BHMT | |
| SCHEMBL29022216 | 0.74 | RNPEP (0.37) | RNPEPANPEPENPEPMETAP2METAP1 | |
| SCHEMBL31397604 | 0.73 | RNPEP (0.36) | RNPEPANPEPENPEPMETAP2METAP1 | |
| Racemethionine SCHEMBL187871 | 0.72 | BHMT (0.49) | RNPEPNOS2NOS3NOS1BHMT | |
| Methionine SCHEMBL187874 | 0.72 | BHMT (0.49) | RNPEPNOS2NOS3NOS1BHMT | |
| Racemethionine SCHEMBL23361954 | 0.71 | BHMT (0.57) | RNPEPNOS2NOS3NOS1BHMT | |
| SCHEMBL3316021 | 0.71 | — | — | |
| Methionine SCHEMBL162030 | 0.71 | BHMT (0.57) | RNPEPNOS2NOS3NOS1BHMT | |
| Racemethionine SCHEMBL8983115 | 0.71 | BHMT (0.57) | RNPEPNOS2NOS3NOS1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1927598-A1 | Vaccine | GlaxoSmithKline Biologicals SA (BE) | 2008-06-04 | — | — | EP | disclosed |
| US-20070161083-A1 | Codon Optimized Recombinant Dermaphagoides Allergens | GLAXOSMITHKLINE BIOLOGICALS, SA | 2007-07-12 | — | — | US | disclosed |
| US-20070122423-A1 | DERP1 AND PRODERP1 ALLERGEN DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS SA | 2007-05-31 | — | — | US | disclosed |
| US-7173117-B2 | Codon optimised recombinant Dermaphagoides allergens | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20060233839-A1 | Novel compounds | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2006-10-19 | — | — | US | disclosed |
| EP-1597277-A2 | HYPOALLERGENIC DER P 1 AND DER P 3 PROTEINS FROM DERMATOGRAPHOIDES PTERONYSSINUS | GlaxoSmithKline Biologicals S.A. (BE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040234538-A1 | Derp1 and proderp1 allergen derivatives | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004076481-A2 | HYPOALLERGENIC DER P 1 AND DER P 3 PROTEINS FROM DERMATOGRAPHOIDES PTERONYSSINUS | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2004-09-10 | — | — | WO | disclosed |
| EP-1417226-A1 | DERP1 AND PRODERP1 ALLERGEN DERIVATIVES | GlaxoSmithKline Biologicals S.A. (BE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030138441-A1 | Codon optimised recombinant dermaphagoides allergens | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2003-07-24 | — | — | US | disclosed |
| EP-1315746-A1 | CODON OPTIMISED RECOMBINANT DERMAPHAGOIDES ALLERGENS | GlaxoSmithKline Biologicals S.A. (BE) | 2003-06-04 | — | — | EP | disclosed |
| WO-2003016340-A1 | DERP1 AND PRODERP1 ALLERGEN DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2001096385-A1 | CODON OPTIMISED RECOMBINANT DERMAPHAGOIDES ALLERGENS | SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060233839-A1 | Novel compounds | HRH1, HRH4, DERL1 | RNPEP 308/4885ANPEP 258/4885ENPEP 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.